FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) is with Takeda Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Tokyo, President: Christoph Webber, hereinafter Takeda Pharmaceutical) , Has signed a license agreement to introduce the drug discovery support AI system developed by FRONTEO.

　The drug discovery support AI system provided by FRONTEO to Takeda Pharmaceutical is our original natural language analysis AI "Concept Encoder (concept encoder).^®, Concept encoder) ”is a system for searching for new drug target candidates.

　In drug discovery research, it is an important process to refer to treatise information and public databases on a daily basis and update information on development.On the other hand, keeping track of domestic and international trends in pharmaceutical research in a timely manner is a heavy burden for researchers and is one of the challenges.Our drug discovery support AI system includes PubMed^{* 1}And Open Targets^{* 2}The latest databases and treatises that exist in Japan are trained, and the treatises and pharmaceutical research data that "Concept Encoder" should refer to can be displayed instantly by simply inputting hypotheses and information that researchers want to know. I can. With this mechanism, FRONTEO will support the allocation of resources that will lead to significant efficiency in drug discovery work and innovation, as well as the proposal of drug repositioning (reuse of existing drugs).

　In addition, this license agreement also includes the provision of an environment in which "Concept Encoder" can analyze data obtained by converting morphological elements and sentences into vectors, and researchers can create their own based on past experimental data and literature information. It is also possible to build a paper analysis AI system.By utilizing the original prediction model using in-house data, it is possible to build new hypotheses driven by data, not just experience and subjectivity, and contribute to the creation of innovative new drugs.

　FRONTEO aims to shift the paradigm of problem solving in drug discovery by improving the efficiency of hypothesis verification using AI.

* 1 PubMed: A database that allows you to search for biological and medical treatises. Located in the NLM (National Library of Medicine)
Created by NCBI (National Center for Biotechnology Information).
* 2 Open Targets: Database for drug discovery target discovery through public-private partnership

Literature search result screen.A sphere that expresses the relationship (top) and a plane that expands it (bottom).

■ Concept Encoderabout　URL: https://lifescience.fronteo.com/

"Concept Encoder (concept encoder)^®, Concept Encoder) ”is a natural language analysis AI (artificial intelligence) developed by FRONTEO specializing in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. "Concept Encoder" can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■ FRONTEOabout　URL: https://www.fronteo.com/

FRONTEO Inc. has developed its own natural language analysis AI (artificial intelligence) engine "KIBIT".^®(Kibit) ”and“ concept encoder^®(Concept encoder) ”is a company that supports information analysis.Established in August 2003 as a company that supports e-discovery (electronic discovery), which preserves evidence, investigates and analyzes electronic data necessary for international proceedings, and digital forensic investigations, and technologies such as an in-house developed data analysis platform To date, we have supported about 8 international proceedings.In addition, we are applying the unique AI-related technology cultivated in the legal business to areas such as life science and business intelligence, and have achieved results in drug discovery research support, diagnostic support, and work style reform. Listed on TSE Mothers on June 1, 2007.The capital is 6 thousand yen (as of March 26, 2,559,206).